Left Ventricular Assist Device Therapy in Heart Failure: A Meta-Analysis

Kerdany, Ahmed Baheig Hosny El; Metwally, Hany Abd El Maabood; Khorshid, Ramy; Esmaiel, Sandy Yasser

doi:10.21608/asmj.2021.167363

Ain Shams Medical Journal

2021

DOI: 10.21608/asmj.2021.167363

|View full text |Cite

Left Ventricular Assist Device Therapy in Heart Failure: A Meta-Analysis

Ahmed Baheig Hosny El Kerdany

Hany Abd El Maabood Metwally

Ramy Khorshid

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Heartware ventricular assist device versus HeartMate II versus HeartMate III in advanced heart failure patients: A systematic review and meta-analysis

Hanafy,

Husen,

Angelica

et al. 2024

SAGE Open Medicine

View full text Add to dashboard Cite

Objective:Ventricular assist device is one of the treatment options for heart failure patients. Therefore, the purpose of this review is to aid in clinical decision-making of exchanging previous older ventricular assist device models to the newest one, HM3.Methods:The search was conducted across several databases until February 25, 2023, and was registered with the ID of CRD42023405367. Risk of bias was performed using Cochrane Risk of Bias 2.0 and the Newcastle Ottawa Scale. In order to rank and evaluate the pooled odds ratios and mean differences with 95% confidence intervals, we employed conventional and Bayesian network meta-analysis converted to surface under the cumulative ranking.Results:A total of 49 studies with 31,105 patients were included in this review. HM3 is the best device exchange choice that causes the lowest risk of mortality (HM3 (99.98) > HM2 (32.43) > HVAD (17.58)), cerebrovascular accidents (HM3 (99.99) > HM2 (42.41) > HVAD (7.60)), other neurologic events beside cerebrovascular accident (HM3 (91.45) > HM2 (54.16) > HVAD (4.39)), pump thrombosis (HM3 (100.00) > HM2 (39.20) > HVAD (10.80)), and bleeding (HM3 (97.12) > HM2 (47.60) > HVAD (5.28)). HM3 is also better than HM2 in hospital admissions (OR: 1.90 (95% CI: 1.15–3.12)). When complications were present, HM2 or Heartware ventricular assist devices exchange to HM3 lowered the mortality rate compared to exchanging it to the same device type.Conclusion:HM3 is the best device for all six outcomes. Exchange from Heartware ventricular assist devices or HM2 to HM3 rather than the same ventricular assist device type is recommended only if a complication is present.

show abstract

Heartware ventricular assist device versus HeartMate II versus HeartMate III in advanced heart failure patients: A systematic review and meta-analysis

Hanafy,

Husen,

Angelica

et al. 2024

SAGE Open Medicine

View full text Add to dashboard Cite

show abstract

Predictors of Gastrointestinal Bleeding in Patients Following Left Ventricular Assist Device Implantation: A Systematic Review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Aim: Our study aims to provide a more holistic understanding of the available data and predictive risk factors for gastrointestinal bleed (GIB). Materials & methods: We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials and Web of Science Core Collection and calculated relative risk and meta-regression was utilized to evaluate for risk factors in order to assess the effect of covariates. Results: Our meta-analysis reported a pooled prevalence rate of GIB of 24.4%. Meta-regression analysis did not yield a statistically significant association between GIB and risk factors, including age, gender, hypertension, chronic kidney disease and diabetes. Conclusion: Studies investigating larger sample sizes are required for conclusive findings.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Left Ventricular Assist Device Therapy in Heart Failure: A Meta-Analysis

Cited by 2 publications

References 24 publications

Heartware ventricular assist device versus HeartMate II versus HeartMate III in advanced heart failure patients: A systematic review and meta-analysis

Heartware ventricular assist device versus HeartMate II versus HeartMate III in advanced heart failure patients: A systematic review and meta-analysis

Predictors of Gastrointestinal Bleeding in Patients Following Left Ventricular Assist Device Implantation: A Systematic Review and meta-analysis

Contact Info

Product

Resources

About